Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 40.29 USD -1.44% Market Closed
Market Cap: 1.4B USD

EV/EBIT
Enterprise Value to EBIT

-0.4
Current
0
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.4
=
Enterprise Value
747.5m USD
/
EBIT
-2.1B USD
Market Cap EV/EBIT
US
Grail Inc
NASDAQ:GRAL
1.4B USD -0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 317.8
US
Abbvie Inc
NYSE:ABBV
336.1B USD 22.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 27.2
US
Epizyme Inc
F:EPE
94.1B EUR -565.3
AU
CSL Ltd
ASX:CSL
131.1B AUD 24
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 13.6
US
Seagen Inc
F:SGT
39.3B EUR -60.1
EBIT Growth EV/EBIT to Growth
US
Grail Inc
NASDAQ:GRAL
Average EV/EBIT: 21.1
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 317.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
24
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.4
2-Years Forward
EV/EBIT
-1.4
3-Years Forward
EV/EBIT
-1.4